News & Updates

Single-lead ECGs may not be as accurate in detecting AF as previously thought

A new study has challenged previously reported accuracy of atrial fibrillation (AF) detection with single-lead electrocardiograms (ECGs) technology.

Dexmedetomidine protects against new-onset AF in critically ill patients

The use of dexmedetomidine in the intensive care unit (ICU) appears to lower the risk of new-onset atrial fibrillation (AF) in patients, according to a study.

Managing MDR gram-negative bacterial infections: Key lessons from 5 years of using ceftazidime-avibactam

The rapid emergence of multidrug-resistant (MDR) pathogens is a major and persistent global healthcare problem. In a Pfizer-sponsored symposium held during the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), experts shared lessons drawn from over half a decade of using ceftazidime-avibactam in the management of MDR gram-negative bacterial infections. Prof David Paterson from the National University of Singapore and Dr Maddalena Giannella from Bologna University, Italy chaired the session. 

Among the highlights were real-world evidence (RWE) with ceftazidime-avibactam and how it has shaped the anti-infective therapeutic landscape, the importance of early, appropriate treatment and its place in antimicrobial stewardship strategies, and the roles of microbiology and diagnostics in optimizing treatment strategies.

Using visual acuity to guide diabetic macular oedema treatment

Diabetic macular oedema (DME) patients with visual acuity (VA) of 20/50 or worse are likely to experience superior clinically relevant VA outcomes at 1 year and over 2 years using aflibercept vs bevacizumab or ranibizumab, according to an analysis of Diabetic Retinopathy Clinical Research (DRCR) Network’s Protocol T data presented at the 38^th Asia-Pacific Academy of Ophthalmology (APAO 2023) Congress.